Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MSP008 22

Drug Profile

MSP008 22

Alternative Names: MSP-008-22; MSP008-22-35-01

Latest Information Update: 18 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Godavari Biorefineries
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I COVID 2019 infections; Solid tumours

Most Recent Events

  • 01 Oct 2022 Phase-I clinical trials in COVID-2019 infections (In volunteers, In adults) in India (PO) (NCT05532293)
  • 01 Sep 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in India (PO) (NCT05478486)
  • 28 Jul 2022 Godavari Biorefineries plans a phase I trial in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease) in India (PO, Tablet) in September 2022 (NCT05478486)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top